

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p style="font-size: 2em; font-weight: bold; text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p>		<p style="text-align: center;">Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/728,055</td> </tr> <tr> <td>Filing Date</td> <td>December 4, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>George Mulligan</td> </tr> <tr> <td>Group Art Unit</td> <td>1642</td> </tr> <tr> <td>Examiner Name</td> <td>Reddig, Peter J.</td> </tr> <tr> <td>Attorney Docket Number</td> <td>MPI02-202P1RNM</td> </tr> </table>		Application Number	10/728,055	Filing Date	December 4, 2003	First Named Inventor	George Mulligan	Group Art Unit	1642	Examiner Name	Reddig, Peter J.	Attorney Docket Number	MPI02-202P1RNM
Application Number	10/728,055														
Filing Date	December 4, 2003														
First Named Inventor	George Mulligan														
Group Art Unit	1642														
Examiner Name	Reddig, Peter J.														
Attorney Docket Number	MPI02-202P1RNM														
Sheet	1	of	1												
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS															
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²												
/PR/	C15	Agnelli, Luca, et al., Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing <i>CCND1</i> and negative for 14q32 translocations," <i>Journal of Clinical Oncology</i> , Vol. 23, No. 29 (October 10, 2005) pp 7296-7306													
/PR/	C16	Bryant, B., e al., "Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib," Gene expression omnibus [online], National Center for Biotechnology Information, GEO Data Set Accession No. GSE9782, [retrieved March 11, 2008]													
Examiner Signature	/Peter Reddig/		Date Considered 06/16/2008												

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.